The Newsroom

Investigations  /  06.12.2019

Shareholder Investigation of Ra Medical Systems

Ra Medical Systems, Inc. (RMED) Misled Shareholders

According to the complaint against the company for alleged violations of the Securities and Exchange Act of 1933 pursuant to its September 2018 initial public offering (“IPO”), Ra Medical Systems, Inc. (RMED) held its IPO and received approximately $67.6 million in proceeds. The proceeds from the IPO were purportedly to be used for expansion of its direct sales force and marketing of its products; clinical studies for new products and product enhancements; and other research and development activities, working capital, and general corporate purposes. However, in March 2019, Ra Medical revealed that its financial results were negatively impacted by issues related to the hiring and training of qualified sales personnel as well as production limitations. On this news, Ra Medical’s stock fell over 30% to close at $4.43 per share on March 15, 2019. As of June 11, 2019, Ra Medical was trading at $3.09, an over 80% decline from its IPO price.

Ra Medical Systems, Inc. (RMED) Systems Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can please send us a message via the Shareholder Information form below.

Shareholder Information

  • Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

How can we help you?

CONTACT US TODAY | 1-800-350-6003 or info@robbinsarroyo.com

Tell us your concerns